Centocor Diagnostics development of P-selectin heart attack test to be funded by IPO.
This article was originally published in The Gray Sheet
CENTOCOR DIAGNOSTICS' DEVELOPMENT OF HEART ATTACK PREDICTION TEST would be funded by $20 mil. from a proposed initial public offering by the Centocor subsidiary. The P-selectin Profile test is designed to facilitate emergency room triage of patients suffering from acute coronary syndrome. Centocor is developing clinical lab assays and a point-of-care instrument to test for P-selectin.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.